Simvastatin Therapy in Multiple Sclerosis Patients with Respect to Gut Microbiome-Friend or Foe?
To the Editor;
There are some reports indicating positive effect of simvastatin in promoting remyelination in multiple sclerosis (MS) patients (Kremer et al. 2018). In addition to this effect, simvastatin also reported to have beneficial effects in the treatment of secondary progressive multiple sclerosis (SPMS) (Chan et al. 2017). Despite these positive effects of simvastatin in MS pathogenesis, its effect on gut microbiome of patients has been ignored in the literature.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S et al (2017) Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol 16(8):591–600CrossRefGoogle Scholar
- Kirby T, Ochoa-Repáraz J (2018) The gut microbiome in multiple sclerosis: a potential therapeutic avenue. Med Sci 6(3):69Google Scholar